LRL1 Antibody

LAIR1 Antibodies: Immune Checkpoint Modulators

LAIR1 (CD305) is a type I transmembrane glycoprotein with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). It regulates immune homeostasis and modulates interactions in tumor microenvironments .

Key Features of LAIR1 Antibodies:

Research Findings:

• Malaria Defense: LAIR1-containing antibodies in Plasmodium falciparum-infected individuals disrupt RIFIN-LAIR1 interactions, enhancing parasite neutralization. MGD21 shows higher affinity than MGM5 due to structural mutations .

• Cancer Applications: Anti-LAIR1 antibodies inhibit AKT/NF-κB pathways in leukemia cells, reducing proliferation . Preclinical studies demonstrate efficacy in AML and B-ALL models .

• Autoimmunity: LAIR1 activation suppresses hyperactive immune responses, making it a target for lupus and rheumatoid arthritis therapies .

LRP1 Antibodies: Multifunctional Therapeutic Agents

LRP1 is a ubiquitously expressed receptor involved in immune regulation, cancer metastasis, and neurodegenerative diseases .

Key Features of LRP1 Antibodies:

Research Findings:

• Cancer Metastasis: IgG1-iS18 reduces adhesion/invasion of lung, liver, and prostate cancer cells by 40–60% in vitro . Surface LRP1 levels correlate with metastatic potential (Pearson’s r > 0.85) .

• Immune Modulation: LRP1 regulates T-cell proliferation and GVHD severity. Anti-LRP1 antibodies restore T-cell activity in leukemia models .

• Commercial Availability: Cell Signaling Technology offers Rabbit anti-LRP1 (#64099) for research use, validated in WB/IP applications .

Comparative Analysis of LAIR1 vs. LRP1 Antibodies

Future Directions

• LAIR1: Bispecific antibodies integrating LAIR1 domains show promise for enhancing antibody diversity in infectious disease and oncology .

• LRP1: Targeted delivery systems for IgG1-iS18 are needed to mitigate off-target effects in non-cancerous tissues .